Q/C Technologies, Inc. (QCLS)
NASDAQ: QCLS · Real-Time Price · USD
4.180
-0.340 (-7.52%)
At close: Oct 21, 2025, 4:00 PM EDT
4.110
-0.070 (-1.67%)
Pre-market: Oct 22, 2025, 5:55 AM EDT

Company Description

Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets.

The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease.

It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression.

The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2).

The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025.

The company was founded in 2014 and is headquartered in New York, New York.

Q/C Technologies, Inc.
Q/C Technologies logo
CountryUnited States
Founded2014
IndustrySoftware - Services
SectorTechnology
Employees2

Contact Details

Address:
1185 Avenue of the Americas, Suite 249
New York, New York 10036
United States
Phone856 848 8698
Websitetnfpharma.com

Stock Details

Ticker SymbolQCLS
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001607963

Key Executives

NamePosition
Ian Rhodes CPAInterim Chief Financial Officer
Dr. Mitchell Glass M.D.Chief Medical Officer and Director
Robert SchatzInvestor Relations Officer